It's not about "earnings" b/c there are none, unless you count that slug of injected cash from Merck, which isn't true earnings. Usually, it's about how much they lost/spent on R&D over the past quarter or year-over-year.
No manipulation here; just normal consolidation after a big run up. As previously stated, no new catalysts on the horizon until updates to clinical data are made public.
Really, this stock is up hugely in the past couple of months. Did you think that trend was going to continue to the moon?
It takes a lot of patience with biotech stocks, and a strong stomach for the volatility. If you have neither, get out.
You really are a newbie. You haven't even been in the stock long enough to know that the earnings for the prior quarter were announced last Monday. The current quarter is not even over yet. It will be another 2 months until those earnings come out. An investor like you should be in MacDonalds or Ford, not in a company with a technology such as this. This stock will correct back to $6 but you should not sell here. Buy, hold, and accumulate on dips. That is my motto with THLD.
May 11 ~ According to Bloomberg http://www.bloomberg.com/quote/THLD:US
Current P/E Ratio (ttm) -
Estimated P/E (12/2012) -
Earnings Per Share (USD) (ttm) -0.5800
Est. EPS (USD) (12/2012) -0.1930
Est. PEG Ratio -
Market Cap (M USD) 337.51
Shares Outstanding (M) 49.13
Enterprise Value (M USD) (ttm) 326.58
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 75.2872
Price/Sale (ttm) 5,443.6993
Dividend Yield (ttm) -
Next Earnings Announcement 05/11/2012